Search Results for keywords:"NIH"

The National Institutes of Health (NIH), part of the Department of Health and Human Services (HHS), is offering a new invention for licensing. This invention involves a pre-fusion stabilized F glycoprotein vaccine immunogen designed to combat human metapneumovirus (hMPV), a virus responsible for respiratory illnesses in children and the elderly. The NIH aims to transfer this federally-funded research technology to commercial developers, enhancing vaccine options. This vaccine candidate shows promise due to its ability to elicit strong neutralizing antibodies and has no current market competition for this specific health issue.

The National Institutes of Health is holding closed meetings of the National Institute on Deafness and Other Communication Disorders Special Emphasis Panels to review grant applications. These meetings, set on February 24 and February 25, 2021, will occur via telephone conference calls and will evaluate clinical trial and chemosensory fellowship applications, respectively. The meetings will be closed to the public to protect confidential information and personal privacy. Contact information for the scientific review officers, Dr. Katherine Shim and Dr. Sheo Singh, is provided for further inquiries.

The National Institutes of Health (NIH), under the Department of Health and Human Services, announced closed meetings for various committees of the Center for Scientific Review. These meetings, held virtually, aim to discuss and evaluate grant applications related to several research topics, including transmission of diseases, cardiovascular and hematology activities, vascular physiology, and drug delivery systems. The meetings are not open to the public to protect confidential information and personal privacy. Meeting dates range from May 19 to June 24, 2025.

In accordance with the Federal Advisory Committee Act, the National Institutes of Health (NIH) have announced several upcoming closed meetings of various committees. These meetings are set to take place virtually at the NIH headquarters in Bethesda, MD, from March to April 2025. The committees will be reviewing and evaluating grant applications, and the discussions will include confidential information, which is why these sessions are not open to the public. Contact details for the scientific review officers in charge of each meeting are provided for those seeking more information.

The National Institutes of Health announced a closed meeting for the National Institute of Allergy and Infectious Diseases' Special Emphasis Panel, scheduled for January 24, 2025. The meeting will discuss and review grant applications and will be closed to protect confidential and personal information. This gathering will take place via video and is not open to the public due to concerns about revealing trade secrets and personal privacy. For more information, Shiv A. Prasad is the contact person at the NIH.

The National Institutes of Health (NIH) is offering a government-owned invention for licensing. This invention is a vaccine that uses a virus vector called VSV-EBOV to express the spike protein of the SARS-CoV-2 virus, which causes COVID-19. The vaccine has shown effective protection against the virus in animal tests, and it only requires a single dose. It is designed to be inexpensive to produce and provides high levels of antibodies to fight COVID-19.

The National Institutes of Health (NIH) will hold a meeting of the HEAL Multi-Disciplinary Working Group to discuss the Helping to End Addiction Long-term Initiative on March 2-3, 2021. The meeting will be partially open to the public and will be webcast live, with sessions closed to protect confidential information. Interested individuals can contact Rebecca G. Baker, Ph.D. for further information or to submit comments. Details and agendas will be available on the NIH HEAL Initiative's website.